1. Chawla, Sant P, Olevsky, Olga, Iyengar, Geeta, Hall, Frederick L, Gordon, Erlinda M. . Early-stage CCNG1+ HR+ HER2+ Invasive Breast Carcinoma in Older Women: Current Treatment and Future Perspectives for DeltaRex-G, a CCNG1 Inhibitor. In Anticancer research, 43, 2383-2391. doi:10.21873/anticanres.16406. https://pubmed.ncbi.nlm.nih.gov/37247916/
2. Xu, Ying, Zhang, Qing, Miao, Chunying, Yang, Xingsheng, Kong, Beihua. 2018. CCNG1 (Cyclin G1) regulation by mutant-P53 via induction of Notch3 expression promotes high-grade serous ovarian cancer (HGSOC) tumorigenesis and progression. In Cancer medicine, 8, 351-362. doi:10.1002/cam4.1812. https://pubmed.ncbi.nlm.nih.gov/30565428/
3. Lin, Tao, Ma, Quanping, Zhang, Yuefeng, Yan, Jiapeng, Gao, Changhong. 2017. MicroRNA-27a functions as an oncogene in human osteosarcoma by targeting CCNG1. In Oncology letters, 15, 1067-1071. doi:10.3892/ol.2017.7389. https://pubmed.ncbi.nlm.nih.gov/29399167/
4. Liu, Yuanyuan, Fu, Xiaomin, Wang, Xiuyun, Liu, Yanling, Song, Xiaoyan. 2021. Long non‑coding RNA OIP5‑AS1 facilitates the progression of ovarian cancer via the miR‑128‑3p/CCNG1 axis. In Molecular medicine reports, 23, . doi:10.3892/mmr.2021.12027. https://pubmed.ncbi.nlm.nih.gov/33760168/
5. Chen, Ye, Yan, Rui, Li, Bo, Song, Wenyu, Zhu, Chunling. 2020. Silencing CCNG1 protects MPC-5 cells from high glucose-induced proliferation-inhibition and apoptosis-promotion via MDM2/p53 signaling pathway. In International urology and nephrology, 52, 581-593. doi:10.1007/s11255-020-02383-4. https://pubmed.ncbi.nlm.nih.gov/32016904/
智鼠故事 
